Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 8Terminated 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Prostatic Hyperplasia 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × TroVax × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT00521274 2016-03-17

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
11 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡